Table 2 Outcome parameters of patients admitted with COVID-19 and ARDS to the Intensive Care Unit.

From: Glycaemic variability is associated with all-cause mortality in COVID-19 patients with ARDS, a retrospective subcohort study

 

N

All

DGV < 25.5 mg/dl

DGV ≥ 25.5 mg/dl

P value

(N = 106)

(N = 59)

(N = 47)

Endpoint at close-out: Survivor

106

53 (50·0%)

41 (69·5%)

12 (25·5%)

 < 0.01

Hospitalisation (days)

106

32.5 (20.0–56.1)

38.0 (28.0–61.7)

23.0 (16.0–38.3)

 < 0.01

ICU (days)

106

28.0 (16.0–44.3)

36.0 (21.5–58.7)

21.0 (10.3–31.8)

 < 0.01

Ventilation (days)

106

25.0 (14.0–44.0)

34.0 (18.3–52.8)

20.0 (10.2–31.8)

 < 0.01

ECMO therapy

106

30 (28·3%)

18 (30·5%)

12 (25·5%)

0.67

Dialysis

106

70 (66·0%)

34 (57·6%)

36 (76·6%)

0.06

Dexamethasone

106

43 (40·6%)

23 (39·0%)

20 (42·6%)

0.84

Glucose, median (mg/dl)

106

149.2 (135.0–168.1)

141.5 (129.0–151.8)

168.0 (148.9–186.8)

 < 0.01

FPG, 3-day median (mg/dl)

106

155.0 (138.0–193.1)

146.0 (129.8–169.0)

185.5 (148.9–210.2)

 < 0.01

DGV (mg/dl)

106

22.5 (15.9–33.0)

16.0 (13.0–20.0)

35.0 (29.5–52.3)

 < 0.01

DGV, 3-day median (mg/dl)

106

31.0 (16.0–55.1)

22.0 (13.2–31.8)

42.0 (32.2–93.5)

 < 0.01

Procalcitonin, median (ng/ml)

106

0.8 (0.3–2.6)

0.5 (0.2–1.5)

1.5 (0.6–4.5)

 < 0.01

  1. Numerical parameters are expressed as median (IQR) and categorical as N (%). The N column represents the number of non-missing values in each row to the right. P-values for differences between the two groups were tested using Fisher’s exact test for categorical variables and Kruskal–Wallis test for continuous variables. Bold indicates significant differences (P < 0.05). Parameters denoted with * are calculated over the first three days (“3-day”) or entire course of ICU admission. Daily glycaemic variability (DGV) is explained in the methods section.
Back to article page